Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 8Thoracic 7Lymphoid 7Gynecologic 6Genitourinary 5Plasma cell 4Gastrointestinal 4CNS 4Sarcoma 3Other solid neoplasm 3Other hematologic neoplasm 3Head & Neck 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Endocrine 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × sapanisertib × Sarcoma × Clear all
NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated
6 enrolled 10 charts
Sarcoma

Sarcoma

NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡